Physician profile
Thomas Bernard
NPI 1962404475
$7,769.54
in general payments reported to CMS, 2019-2025
45 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $703 · 2020: $1,194 · 2021: $1,283 · 2022: $1,347 · 2023: $1,001 · 2024: $1,163 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,242.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $939.91 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $819.10 | 2020-2025 | Trintellix |
| Novo Nordisk INC | $680.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $648.05 | 2019-2025 | Mounjaro, Zepbound |
| Lundbeck LLC | $558.04 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $541.87 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $457.36 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.29 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $285.93 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $243.66 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $184.52 | 2021-2025 | |
| Shire North American Group INC | $177.34 | 2019 | |
| Phathom Pharmaceuticals, INC. | $169.04 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $159.20 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.63 | 2020-2024 | Xifaxan |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bernard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.